Neefe J R, Sullivan J E, Ayoob M, Phillips E, Smith F P
Cancer Res. 1985 Feb;45(2):874-8.
Thirty patients with metastatic colon or breast cancer were treated with recombinant alpha-interferon, clone A, 9 to 50 X 10(6) units/sq m, i.m., 3 times weekly for up to 4 months. Immunological parameters including natural killer activity, antibody-dependent cellular cytotoxicity, an assay of inhibition of tumor cell growth in culture, and quantification of leukocyte subsets were monitored serially. Statistically significant increases in the inhibition of tumor growth and in the proportion of peripheral blood mononuclear cells bearing the T10 marker were observed both early and late in the treatment course in the population as a whole (p less than 0.03 and p less than 0.0001, respectively). The true maximum effect in the assay of inhibition of tumor growth was probably higher, since the monitoring was not performed at peak activity for this assay. Other immune parameters, including natural killing, could not be shown to change consistently in the population as a whole, although interferon effects could be discerned easily in the activity profiles of some individual patients. The two patients with tumor response showed increased putative tumor immunity by these measures. These data confirm results previously published supporting the responsiveness of these parameters to interferon as administered clinically and may provide the basis for optimization of interferon dose and scheduling.
30例转移性结肠癌或乳腺癌患者接受重组α-干扰素A克隆治疗，剂量为9至50×10⁶单位/平方米，肌肉注射，每周3次，持续4个月。连续监测免疫参数，包括自然杀伤活性、抗体依赖性细胞毒性、肿瘤细胞培养生长抑制试验以及白细胞亚群定量。在整个治疗过程的早期和晚期，观察到肿瘤生长抑制和携带T10标志物的外周血单核细胞比例均有统计学显著增加（分别为p<0.03和p<0.0001）。肿瘤生长抑制试验中的真正最大效应可能更高，因为该试验的监测并非在活性峰值时进行。尽管在一些个体患者的活性谱中很容易看出干扰素的作用，但包括自然杀伤在内的其他免疫参数在整个群体中并未显示出一致的变化。两名有肿瘤反应的患者通过这些指标显示出假定的肿瘤免疫力增强。这些数据证实了先前发表的结果，支持这些参数对临床应用的干扰素具有反应性，并可能为优化干扰素剂量和给药方案提供依据。
